Efficacy and Safety of Everolimus with Reduced-Dose Calcineurin Inhibitor in De Novo Kidney Transplant Recipients

2018 ◽  
Vol 102 ◽  
pp. S367 ◽  
Author(s):  
Julio Pascual ◽  
Steve Chadban ◽  
Helio Tedesco ◽  
Stefan Berger ◽  
Yasir Qazi ◽  
...  
2018 ◽  
Vol 29 (7) ◽  
pp. 1979-1991 ◽  
Author(s):  
Julio Pascual ◽  
Stefan P. Berger ◽  
Oliver Witzke ◽  
Helio Tedesco ◽  
Shamkant Mulgaonkar ◽  
...  

Background Everolimus permits reduced calcineurin inhibitor (CNI) exposure, but the efficacy and safety outcomes of this treatment after kidney transplant require confirmation.Methods In a multicenter noninferiority trial, we randomized 2037 de novo kidney transplant recipients to receive, in combination with induction therapy and corticosteroids, everolimus with reduced-exposure CNI (everolimus arm) or mycophenolic acid (MPA) with standard-exposure CNI (MPA arm). The primary end point was treated biopsy-proven acute rejection or eGFR<50 ml/min per 1.73 m2 at post-transplant month 12 using a 10% noninferiority margin.Results In the intent-to-treat population (everolimus n=1022, MPA n=1015), the primary end point incidence was 48.2% (493) with everolimus and 45.1% (457) with MPA (difference 3.2%; 95% confidence interval, −1.3% to 7.6%). Similar between-treatment differences in incidence were observed in the subgroups of patients who received tacrolimus or cyclosporine. Treated biopsy-proven acute rejection, graft loss, or death at post-transplant month 12 occurred in 14.9% and 12.5% of patients treated with everolimus and MPA, respectively (difference 2.3%; 95% confidence interval, −1.7% to 6.4%). De novo donor-specific antibody incidence at 12 months and antibody-mediated rejection rate did not differ between arms. Cytomegalovirus (3.6% versus 13.3%) and BK virus infections (4.3% versus 8.0%) were less frequent in the everolimus arm than in the MPA arm. Overall, 23.0% and 11.9% of patients treated with everolimus and MPA, respectively, discontinued the study drug because of adverse events.Conclusions In kidney transplant recipients at mild-to-moderate immunologic risk, everolimus was noninferior to MPA for a binary composite end point assessing immunosuppressive efficacy and preservation of graft function.


2006 ◽  
Vol 82 (1) ◽  
pp. 62-68 ◽  
Author(s):  
Anders ??sberg ◽  
Karsten Midtvedt ◽  
P??l D. Line ◽  
Janicke Narverud ◽  
Hallvard Holdaas ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document